BioSpace News Archive

Product launch and rapid development of the Logix Smart™ 2019-nCoV coronavirus test facilitated by Company’s proprietary technology platform

To increase the number of healthcare professionals in the Inland Empire and improve Member access to care, Inland Empire Health Plan is thrilled to announce its $40 million commitment over five years to launch the Healthcare Scholarship Fund.

eFFECTOR Therapeutics, Inc. announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 11 at 2:00 p.m. ET.

Collegium Pharmaceutical, Inc. announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc. for $375.0 million in cash..

Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Thursday, February 13, 2020 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2019.

Therapix Biosciences Ltd. announced that on February 5, 2020, it received notice that the Nasdaq Hearings Panel granted the Company an extension until April 1, 2020, to regain compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550.

Brooks Automation, Inc., a leader in automation solutions for the semiconductor manufacturing and life sciences industries, reported financial results for the first fiscal quarter of 2020, ended December 31, 2019.

Cadent Therapeutics announced that the Company’s Cadence-1 study will be highlighted in a poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.

Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today

Aduro Biotech, Inc. announced that the company earned a $10.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer.